Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin Resistance
Diabetes & Metabolism Journal
;
: 89-95, 2017.
Article
Dans Anglais
| WPRIM
| ID: wpr-110922
ABSTRACT
Obesity has quickly become a worldwide pandemic, causing major adverse health outcomes such as dyslipidemia, type 2 diabetes mellitus, cardiovascular disease and cancers. Obesity-induced insulin resistance is the key for developing these metabolic disorders, and investigation to understand the molecular mechanisms involved has been vibrant for the past few decades. Of these, low-grade chronic inflammation is suggested as a critical concept in the development of obesity-induced insulin resistance, and the anti-inflammatory effect of nitric oxide (NO) signaling has been reported to be linked to improvement of insulin resistance in multiple organs involved in glucose metabolism. Recently, a body of evidence suggested that vasodilatory-stimulated phosphoprotein (VASP), a downstream mediator of NO signaling plays a crucial role in the anti-inflammatory effect and improvement of peripheral insulin resistance. These preclinical studies suggest that NO/VASP signaling could be an ideal therapeutic target in the treatment of obesity-related metabolic dysfunction. In this review, we introduce studies that investigated the protective role of NO/VASP signaling against obesity-related inflammation and insulin resistance in various tissues.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Insulinorésistance
/
Endothélium vasculaire
/
Maladies cardiovasculaires
/
Tissu adipeux
/
Diabète de type 2
/
Dyslipidémies
/
Pandémies
/
Glucose
/
Inflammation
/
Insuline
langue:
Anglais
Texte intégral:
Diabetes & Metabolism Journal
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS